ReNeuron to advance stem cell-based stroke therapy trial
This article was originally published in Clinica
ReNeuron has got the go-ahead to expand its PISCES UK Phase I study of its ReN001 foetal-derived stem cell therapy for ischaemic stroke. The trial can now enrol a second cohort of patients who will be treated with a higher dose of ReN001. The first cohort of three patients, who received the lowest dose of therapy, has now been assessed, and no adverse events have been reported.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.